Current Edition

Regional News

FDA greenlights Genentech’s eye implant for macular degeneration. Will it be a tough sell?

Two treatments per year as opposed to 12, what’s not to like? In two words—surgical implants. That’s the stigma Genentech will potentially face as it attempts to con...
Continue Reading →

Opthea’s Phase 2b Wet AMD Clinical Trial Reaches Mid-Way Point of Patient Recruitment

Opthea Recruits 176th Patient and On-Track to Report Primary Data Analysis Early 2020 Opthea Limited (ASX:OPT), a late stage biopharmaceutical company developing nove...
Continue Reading →